TimesSquare Capital Management LLC Has $74.79 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

TimesSquare Capital Management LLC reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 500,920 shares of the biotechnology company's stock after selling 95,394 shares during the quarter. Ascendis Pharma A/S makes up 1.1% of TimesSquare Capital Management LLC's portfolio, making the stock its 25th largest holding. TimesSquare Capital Management LLC owned approximately 0.83% of Ascendis Pharma A/S worth $74,792,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after purchasing an additional 336,976 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock valued at $1,664,000 after acquiring an additional 4,338 shares during the period. Evolutionary Tree Capital Management LLC raised its stake in Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock valued at $3,391,000 after acquiring an additional 11,223 shares during the period. SG Americas Securities LLC increased its position in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock worth $833,000 after buying an additional 4,205 shares during the period. Finally, Acadian Asset Management LLC increased its position in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company's stock worth $37,849,000 after buying an additional 234,446 shares during the period.

Analyst Ratings Changes

Several research firms have recently issued reports on ASND. Evercore ISI increased their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a report on Tuesday, September 17th. Bank of America lifted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, November 4th. TD Cowen boosted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Wedbush raised Ascendis Pharma A/S to a "strong-buy" rating in a research report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Down 1.8 %

ASND traded down $2.22 during midday trading on Friday, hitting $124.33. The company's stock had a trading volume of 459,304 shares, compared to its average volume of 361,298. The firm has a market cap of $7.54 billion, a P/E ratio of -13.35 and a beta of 0.66. The firm has a 50-day moving average price of $132.26 and a two-hundred day moving average price of $133.09. Ascendis Pharma A/S has a 52-week low of $86.54 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts expect that Ascendis Pharma A/S will post -7.35 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.